You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
百濟神州(06160.HK)百澤安聯合化療在鼻咽癌患者中顯示無進展生存期獲益
百濟神州(06160.HK)公布,公司將在美國臨床腫瘤學會全體大會系列會議上公布3期臨床試驗RATIONALE309的更新數據分析,試驗旨在研究百澤安聯合化療對比安慰劑聯合化療作為復發或轉移性鼻咽癌(RM-NPC)患者的一線治療效果。 更新後的有效性分析表明,在中位隨訪時間為15.5個月時,百澤安聯合化療相比於單獨化療,在RM-NPC患者中仍顯示出具有臨床意義的無進展生存期獲益。百澤安和化療聯合用藥的安全性特徵總體可控,且與每種治療藥物的已知風險一致。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account